Bristol Study Finds Tocilizumab Lifts Treatment-Resistant Depression in 30-Patient Trial
Updated
Updated · Moneycontrol · May 29
Bristol Study Finds Tocilizumab Lifts Treatment-Resistant Depression in 30-Patient Trial
2 articles · Updated · Moneycontrol · May 29
54% of patients given tocilizumab reached remission in the four-week pilot trial, versus 31% on placebo, among adults whose depression had not improved with standard antidepressants.
30 participants with moderate-to-severe depression also showed broader gains on the anti-inflammatory drug, including lower anxiety, less fatigue and better day-to-day functioning.
IL-6, an inflammatory signal linked to depressive symptoms, is central to the study’s rationale; researchers say about one in three people with depression show raised inflammation markers.
Larger trials are still needed before tocilizumab could be used routinely, but the findings add to a growing push for biology-based, precision treatment of depression.
Could a simple blood test soon unlock a new cure for treatment-resistant depression?
Is depression not just in the mind, but a body-wide inflammatory disease for millions?
Immunotherapy for Depression: Pilot Trial Shows 54% Remission with Tocilizumab, Paving Way for Precision Psychiatry
Overview
In May 2026, the University of Bristol led a pilot clinical trial that brought new hope for people with difficult-to-treat depression. This double-blind, proof-of-concept study tested the safety and early effectiveness of immunotherapy using tocilizumab, with 30 participants recruited through partnerships with Cambridge institutions. Over four weeks, researchers closely monitored the participants for both benefits and side effects. The trial was well-supported by major funders, and the encouraging results suggest that immunotherapy could become a promising new treatment path for depression, paving the way for larger, more definitive studies in the future.